AnnJi Pharmaceutical Began U.S. Phase 3 SBMA Drug Trial
The company has launched the American portion of a global study for its investigational spinal muscular atrophy treatment.
Updated on Oct. 5, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical companies prioritize the development of new treatments for rare, inherited diseases?
AnnJi Pharmaceutical has initiated the United States portion of the Phase 3 ROMA-KD clinical trial for AJ201. This investigational oral small molecule is being tested as a treatment for spinal and bulbar muscular atrophy.
Why it matters
Spinal and bulbar muscular atrophy is an inherited neuromuscular disease that currently has no FDA-approved treatments. The ongoing global trial aims to provide the necessary data to support future regulatory submissions.
The ROMA-KD trial is a randomized, double-blind, placebo-controlled study with an expected enrollment of 200 patients globally. AJ201 has received both Orphan Drug and Fast Track designations from the U.S. FDA.
The players
AnnJi Pharmaceutical
Based in Taipei, this pharmaceutical company is developing therapies for rare neuromuscular diseases.
The details
AJ201 functions by promoting the clearance of mutant androgen receptor proteins while activating Nrf1, Nrf2, and HSF1 cellular stress-response pathways. To support the research process, AnnJi Pharmaceutical has established an SBMA Patient and Care Partner Advisory Council.
Timeline
May 2025: AnnJi completed a Phase 2 study of AJ201.
October 5, 2026: AnnJi announced the advancement of the U.S. Phase 3 trial.
The Big Picture
The clinical trial process for AJ201 operates under the incentives of the U.S. FDA Orphan Drug Designation program. This framework is designed to accelerate the development of therapies for rare diseases that currently lack any standard treatment options.
Patients suffering from spinal and bulbar muscular atrophy currently lack any approved medical interventions for their condition. The success of this global trial could eventually introduce the first recognized pharmacological treatment to the healthcare market.
The takeaway
This trial represents a significant step forward in addressing an unmet need for patients with inherited neuromuscular disorders. Researchers are now observing whether the drug's specific molecular mechanisms successfully translate into meaningful patient outcomes during the trial.
Further reading
Learn more about the latest research in this field by visiting our Alzheimer’s section.
Live Poll
Should pharmaceutical companies prioritize the development of new treatments for rare, inherited diseases?
